HomeClinical TopicsFDA approves treatments for irritable bowel syndrome

FDA approves treatments for irritable bowel syndrome

On May 27, the U.S. Food and Drug Administration (FDA) approved Viberzi (eluxadoline) and Xifaxan (rifaximin) for irritable bowel syndrome with diarrhea in adult men and women. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Recent Content